Abstract
The optimal role of immunosuppressive therapy in the treatment of IgA nephropathy is controversial. Results of a recently completed randomized controlled trial provide strong support for comprehensive supportive care rather than immunosuppressive therapy in patients at high risk for progression.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Antihypertensive Agents / therapeutic use
-
Glomerular Filtration Rate
-
Glomerulonephritis, IGA / drug therapy*
-
Glomerulonephritis, IGA / physiopathology
-
Glomerulonephritis, IGA / therapy
-
Humans
-
Hypertension / drug therapy
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Proteinuria / drug therapy
-
Randomized Controlled Trials as Topic
-
Renin-Angiotensin System / drug effects
Substances
-
Antihypertensive Agents
-
Immunosuppressive Agents